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ABSTRACT
Docetaxel belongs to taxane family of antineoplastic agents that are indicated for the treatment of locally advanced or metastatic non-small-cell lung 
cancer. Docetaxel is associated with many adverse effects, and pulmonary reaction has an incidence of 41%. However, interstitial pulmonary disease 
is found to occur only in <1% of the population as per the post-marketing surveillance reports. Here, we report a case of docetaxel-induced interstitial 
lung disease (ILD). The patient information and details were collected using the hospital information system. The adverse drug reaction (ADR) of ILD 
occurred after 5 cycles of chemotherapy with docetaxel at a dose of 60 mg/m2 that is 80 mg IV. The causality of the event in our case was assessed 
using the Naranjo ADR probability scale which marked a score of 7 (probable). It is necessary that all physicians be aware of the reaction and to closely 
monitor clinicoradiological and functional status of the patients at regular intervals after administration of docetaxel.
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INTRODUCTION
Interstitial lung disease (ILD) is a group of diseases affecting the 
interstitium which is a delicate, thin lining between the lung’s alveoli 
that contain the blood vessels for gas exchange between the alveoli [1]. 
Docetaxel belongs to the taxane family of antineoplastic agents that are 
indicated for the treatment of locally advanced or metastatic breast 
cancer, locally advanced or metastatic non-small-cell lung cancer, 
hormone refractory prostate cancer, gastric adenocarcinoma, and 
squamous cell carcinoma of the head and neck cancer [2]. The extract of 
the European yew, Taxus baccata is the source from where docetaxel is 
being derived [3]. It is commonly sold under the brand name Taxotere.
The anticancer properties of docetaxel are by promoting tubulin 
assembly thus forming stable microtubules and by inhibiting tubulin 
depolymerization which leads to stabilization of microtubules in the 
cell. This inturn inhibits protein, deoxyribonucleic acid, and ribonucleic 
acid synthesis leading to the arrest of cell mitosis in the M phase of 
cell cycle. Since docetaxel is known to prevent the depolymerization 
of microtubules, it is cytotoxic against human ovarian, endometrial, 
colon, and breast cancer. When compared with insoluble paclitaxel, 
docetaxel which is soluble shows more cytotoxicity [4]. The most 
common adverse events (>10%) associated with docetaxel include fluid 
retention, alopecia, central nervous system reactions (neuropathy), 
dermatological reactions, stomatitis, nausea, vomiting, diarrhoea, 
elevated serum transaminases, neutropenia, thrombocytopenia, 
leukopenia, anemia, myalgia, neuromuscular reaction, nail disease and 
pulmonary reaction. Pulmonary reactions associated with docetaxel 
are found to be approximately 41%. Among the pulmonary reactions, 
interstitial pulmonary disease is found to occur only in <1% of the 
population as per the post-marketing surveillance reports. Here, we 
report the case of ILD after 5 cycles of chemotherapy with docetaxel 
which is a rare adverse effect of the drug.
CASE REPORT
A 34-year-old female who is a known case of carcinoma breast with 
bone marrow metastasis and adnexal mass under evaluation presented 
to Pulmonary Medicine Department with complaints of grade 2 
dyspnea of 2-week duration and dry cough. She was on chemotherapy 
with Docetaxel (60 mg/m2 that is 80 mg IV) - completing 5 cycles 
and the 5th cycle being completed 9 days before the presentation. On 
examination, the patient had basal crepitations, and a chest X-ray was 
taken which showed bilateral reticulonodular shadows with right sided 
pleural effusion (Fig. 1), In view of pleural effusion, chemotherapy with 
docetaxel was discontinued.
Positron emission tomography (PET)/computed tomography (CT) 
images in the previous month (Fig. 2) as discussed with nuclear 
medicine and radiology consultants showed moderate bilateral pleural 
effusion but no evidence of ILD.
Pulmonary function test (PFT) done showed severe restriction 
(Table 1) and diffusing capacity for carbon monoxide showed severe 
reduction. The 6 minutes’ walk test (6MWT) examination indicated 
Grade 5 dyspnea. CT thorax Fig. 3 was done which showed bilateral 
pleural effusion with mild ground-glass opacity on bilateral lung 
parenchyma indicative of ILD. Pleural fluid aspiration was done and 
sends for cytology tests. Cytology revealed exudative effusion with low 
adenosine deaminase, negative for malignancy.
As the patient had significant effort intolerance, exercise-induced 
severe desaturation, and radiological evidence of ILD, she was initiated 
on systemic steroids for the next 10 days along with a course of 
antibiotics for 1 week (tab cefpodoxime 200 mg 1-0-1 * 1 week). After 
10 days steroid therapy, patient symptomatically improved with good 
effort tolerance. Repeat chest X-ray showed left shallow pneumothorax, 
and PFT indicated mild improvement (Table 1). Distance covered in the 
6MWT increased to 420 m (99-81%) from 240 m and further increased 
on a later date (Table 1).
As the patient had subjective and clinical improvement (Table 1) with 
systemic steroids, she was planned to be kept under close follow-up 
with oral steroids (tab prednisolone 40 mg for 1 week and later 30 mg 
1-0-0 for the next 1 week). Chest X-ray after 2 week showed reduction 
in the interstitial shadow with complete resolution of pneumothorax 
(Fig. 4). She was advised to continue oral steroids in tapering doses 
depending on the functional and clinicoradiological improvement and 
was initiated on tamoxifen for cancer management.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i10.19043
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DISCUSSION
Docetaxel/paclitaxel in combination with trastuzumab is now 
considered as the first-line treatment for tumors with human epidermal 
growth factor receptor 2 over expression, that is, for patients with 
metastatic disease who have not taken chemotherapy [5]. Our patient 
was on docetaxel monotherapy. On reviewing the side effect profile of 
the drug, the incidence of docetaxel-inducing interstitial pulmonary 
disease is <1% and thus the occurrence of docetaxel-induced ILD is 
rare. However, recently many case reports concerning this reaction 
have been published. The proposed mechanism by which taxanes are 
known to cause pulmonary toxicity is by:
•	 Promotion	of	cytotoxic	T-cell	proliferation	causing	a	hypersensitivity	
type of reaction leading to lung damage,
•	 Promotion	of	reactive	oxygen	metabolites	causing	direct	pulmonary	
damage.
As demonstrated in our case report, the reaction responds to drug 
discontinuation and steroid therapy. However, if the treatment is 
delayed, it can even lead to respiratory failure [6].
The docetaxel-induced ILD usually occurred after the second to 
the fourth course of chemotherapy and was usually relieved by 
corticosteroid therapy [7]. However, in our case, interstitial features 
were exhibited after the 5th course of docetaxel which may be due to the 
concomitant steroid therapy given to the patient.
Wang et al. reported a case of pulmonary toxicity of ILD which 
developed 3 days after docetaxel therapy. The reaction was confirmed 
by diffuse interstitial infiltrates in the chest X-ray and diffuses ground 
glass opacities in bilateral lung fields in chest CT [6]. The dose was 
reported to be 30 mg/m2 which is relatively a low dose when compared 
to the dose in our case (60 mg/m2) which indicates that even a low dose 
can cause a significant reaction. This also suggests that the incidence of 
ILD is not dose related.
Studies indicate that patients on a weekly schedule of docetaxel are 
more vulnerable to pneumonitis than patients on triweekly schedule. 
However, weekly schedule of docetaxel reported lower incidence of 
myelosuppression when compared to triweekly schedule indicating 
that the incidence of pulmonary toxicity is more related to the delivery 
schedule of docetaxel rather than its dose [3,8-10]. However, in our case, 
the patient developed pneumonitis despite the adoption of triweekly 
Fig. 1: Chest X-ray after 5 cycles of docetaxel administration
Fig. 2: Computed tomography taken before docetaxel therapy 
showing clear lung fields
Fig. 3: Computed tomography showing ground glass opacities and 
pleural effusion after 5 cycles of docetaxel therapy
Fig. 4: Chest X-ray showing reduced reticulonodular shadows 
after steroid therapy
Table 1: Comparison of laboratory parameters - after 5 cycles 
of docetaxel therapy versus on discontinuation of docetaxel 
therapy and initiation of steroid therapy
Parameters After 5 cycles of 
docetaxel therapy
On discontinuation of 
docetaxel therapy and 




6MWT SpO2 reduced from 96% 
to 79% after covering a 
distance of 240 m
SpO2 reduced from 98% 
to 82% after covering a 
distance of 440 m
FEV1: Forced expiratory volume in 1s, FVC: Forced expiratory vital capacity, 
6MWT: 6 minutes’ walk test
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administration schedule of docetaxel thus a more keen monitoring of 
the patients should be conducted even if they are on a triweekly dosing 
schedule.
Storaas et al. also reported a case of a breast cancer patient who 
developed pneumonitis during docetaxel therapy which was severe and 
progressive in nature. The reaction was observed after four courses of 
twice weekly schedule of I.V. docetaxel 100 mg/m2 and was found to be 
steroid resistant. The pneumonitis was worsened by other complications 
such as severe hypercapnia and hypoxia, bilateral pneumothorax, and 
reduced lung compliance because of which the patient died in the 
intensive care unit after 20 days of advanced ventilator supports [8].
The largest series of docetaxel associated interstitial pneumonitis was 
published by Tamiya et al. which consisted of 392 patients with metastatic 
non-small-cell lung cancer, of which 18 cases of ILD were reported with 
tri-weekly schedule of a higher dose of docetaxel (75 mg/m2) thus 
marking an incidence of 4.6%. The study suggested that approximately 
10-20 days, that is, a median time of 18 days was the time elapse from 
the last docetaxel administration to the onset of toxicity findings on the 
chest X-ray [11]. For our patient, the time taken for the onset of toxicity 
after the last docetaxel administration was approximately 9 days which 
is slightly contrary to the above study findings.
Another case series reported 4 cases of ILD within 8-14 days of 
receiving a second or third cycle of docetaxel followed by progression 
into respiratory failure that required mechanical ventilation. The 
symptoms were insidious in onset the reaction was not responding 
to broad spectrum antibiotics and corticosteroids and 2 patients died 
of pulmonary complications whereas the other 2 required more than 
3 week of ventilatory support. This study also establishes ILD as a 
complication of docetaxel treatment even after rendering corticosteroid 
premedication. The study concludes that aggressive pulmonary support 
can be provided for the management of such reactions if the patient is 
having a favorable prognosis.
A life-threatening ILD requiring ventilator support after docetaxel 
therapy (NSCLC) was reported in 4 patients with advanced non-small-
cell lung cancer [3]. Even though docetaxel was administered as an 
infusion within 1 hr at a dose of 30-60 mg/m2 after giving the standard 
premedication, one among the 4 patients was diagnosed to have ILD 
5 days after the 1st cycle of docetaxel, and for the other 3, between the 
2nd and 6th cycles.
The causality of the event in our case was assessed using the Naranjo 
adverse drug reaction probability scale which marked a score of 7 
(Probable). Due to the inherent risk and severity of the reaction, 
a rechallenge could not be performed. Docetaxel therapy was 
discontinued upon which the patient’s condition improved and the 
patient was initiated on tamoxifen.
CONCLUSION
Our case report once again demonstrates the occurrence of ILD after 
docetaxel administration. Measures which can be taken to reduce the 
incidence of this reaction include premedication with high dose steroid 
therapy 3 days before initiation of docetaxel therapy, administration of 
concomitant steroid therapy during docetaxel therapy and choosing a 
triweekly dosing schedule. It is necessary that all physicians be aware 
of the reaction and to closely monitor clinicoradiological and functional 
status of the patients at regular intervals after administration of docetaxel.
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